|
|
Article: GENENTECH'S TNKASE APPROVED; BLA SUBMITTED FOR ALLERGY DRUG.
- Article from:
- BIOWORLD Today
- Article date:
- June 6, 2000
- Author:
CopyrightCOPYRIGHT 2000 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Genentech Inc.'s stock rose 18 percent Monday with news that the FDA approved for marketing the thrombolytic agent TNKase and with the company's regulatory submission for its anti-IgE asthma and allergy drug.
The stock (NASDAQ:DNA) closed at $128.56, up $19.437.
TNKase (tenecteplase) is indicated to treat acute myocardial infarction (AMI) and has the potential to cannibalize Genentech's Activase, analysts said.
Anti-IgE is a recombinant humanized monoclonal antibody to immunoglobulin E being developed jointly by South San Francisco- based Genentech, East Hanover, N.J.-based Novartis Pharmaceuticals Corp., and Houston-based Tanox Inc. as a ...
Related newspaper, magazine, and journal articles:
|
|
Article: GENENTECH FILES SUIT AGAINST GENZYME OVER TNKASE PATENT.
BIOWORLD Today;
March 16, 2001 ;
665 words
... ... material for Genzyme related to the TNKase patent, and said Genzyme officials ... Copithorne said. Genentech's TNKase, a single-bolus thrombolytic ... company's cardiovascular products, TNKase and Activase, logged combined sales of $206 ...
|
|